Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Cost-effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain.
Ultralow-dose rituximab in pemphigus: a single-centre experience.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Ultralow-dose rituximab in pemphigus: a single-centre experience.
Ultralow-dose rituximab in pemphigus: a single-centre experience. Br J Dermatol. 2022 03; 186(3):581-583.
View in:
PubMed
subject areas
Antibodies, Monoclonal, Murine-Derived
Humans
Immunologic Factors
Pemphigus
Rituximab
Treatment Outcome
authors with profiles
Kit N. Simpson